Yeo Wico
Non-executive Chairman
Board of DirectorsThe business, the people and the ownership behind Vicplas Intl.
Business overview
Vicplas International’s businesses include medical device contract manufacturing through Forefront. Its shareholder disclosures describe close integration between Forefront and customers’ product teams in developing and producing medical devices.
Listed security
Board & management
Four non-executive board members and four senior executives are disclosed. Walter Tarca is Group CEO and does not sit on the Board; Gan Ying Hui is CFO. Cheng Liang ceased as Group CEO in July2022 and remains Managing Director of the pipes and pipe fittings segment. Cheng Hsheng also became Deputy Managing Director of that segment in October2024.
Toon Chin Liang appears in FY2025 remuneration disclosures but resigned15August2025; he is not presented as current management.
Non-executive Chairman
Board of DirectorsNon-executive Director
Board of DirectorsNon-executive Lead Independent Director
Board of DirectorsNon-executive Independent Director
Board of DirectorsGroup Chief Executive Officer
Group; not a directorChief Financial Officer
GroupGroup Operations Director
GroupManaging Director
Pipes and pipe fittings segment of the GroupRoles listed in Annual Report 2025; current appointments are not independently verified.
Holdings
Share register as at13October2025:511,076,699 voting shares excluding461,000 treasury shares. Top20 holders total413,593,553 shares and80.93%; public holdings32.97%. Registered, beneficial and deemed holdings overlap and are not added.
Three registered percentages differ from rounding against the printed voting share count: Cheng Liang2.74% versus2.75%, DBS Nominees1.12% versus1.11%, Maybank Securities0.52% versus0.51%. Original percentages are retained.
Bird Island Trust terminated28February2025. Jane Rose Philomene Gaines-Cooper has absolute rights to the trust assets while legal title is being transferred; the trustee holds title as nominee pending transfer. CTX's own-account deemed255,168,861 shares arise from charges of280,852,441 shares less25,683,580 released. The separate printed disclosures are preserved.
280,852,441 shares beneficially held; no deemed interest; total 280,852,441 shares; 54.95%.
Substantial shareholder; beneficial holdingNo shares beneficially held; deemed interest of 280,852,441 shares; total 280,852,441 shares; 54.95%.
Substantial shareholder; deemed interest as trustee of Bird Island TrustNo shares beneficially held; deemed interest of 255,168,861 shares; total 255,168,861 shares; 49.93%.
Substantial shareholder; deemed interest for its own account following share chargesTotal interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.
Registered holdings, including nominees and depositories; these do not establish ultimate beneficial ownership. As reported at 2025-10-13 · PDF p. 145
| Registered holder | Interest | Shares / units | Source |
|---|---|---|---|
| Venner Capital S.A. | 280,852,441 shares; 54.95%. | PDF p. 1452025-10-13 | |
| Jane Rose Philomene Gaines-Cooper | 23,854,200 shares; 4.67%. | PDF p. 1452025-10-13 | |
| Cheng Liang | 14,029,497 shares; 2.74%. | PDF p. 1452025-10-13 | |
| Raffles Nominees (Pte) Limited | 13,759,587 shares; 2.69%. | PDF p. 1452025-10-13 | |
| Phillip Securities Pte Ltd | 11,069,494 shares; 2.17%. | PDF p. 1452025-10-13 | |
| UOB Kay Hian Pte Ltd | 10,239,404 shares; 2.00%. | PDF p. 1452025-10-13 | |
| Lim Sim Moi | 9,938,000 shares; 1.94%. | PDF p. 1452025-10-13 | |
| Ho Lai Heng | 6,089,000 shares; 1.19%. | PDF p. 1452025-10-13 | |
| DBS Nominees Pte Ltd | 5,691,702 shares; 1.12%. | PDF p. 1452025-10-13 | |
| David Dangar Henry Honywood Curtis-Bennett | 5,100,000 shares; 1.00%. | PDF p. 1452025-10-13 | |
| OCBC Securities Private Ltd | 4,810,466 shares; 0.94%. | PDF p. 1452025-10-13 | |
| Loh Beng Seng | 4,402,318 shares; 0.86%. | PDF p. 1452025-10-13 | |
| CGS International Securities Singapore Pte Ltd | 3,457,100 shares; 0.68%. | PDF p. 1452025-10-13 | |
| Chua Kim Hua | 3,389,200 shares; 0.66%. | PDF p. 1452025-10-13 | |
| Ng Cher Yan | 3,217,390 shares; 0.63%. | PDF p. 1452025-10-13 | |
| IFast Financial Pte Ltd | 3,029,000 shares; 0.59%. | PDF p. 1452025-10-13 | |
| Christopher Paul Lee | 3,000,000 shares; 0.59%. | PDF p. 1452025-10-13 | |
| Lim Boon Hock | 2,700,585 shares; 0.53%. | PDF p. 1452025-10-13 | |
| Maybank Securities Pte. Ltd. | 2,630,569 shares; 0.52%. | PDF p. 1452025-10-13 | |
| Goh Han Peng (Wu Hanping) | 2,333,600 shares; 0.46%. | PDF p. 1452025-10-13 | |
Group structure
Twelve subsidiaries and the49%Cambodia joint venture are disclosed. Subsidiary table reports ownership interest and voting power at the named holding-parent level. No NCI at year end. All principal activities/countries and explicit subsidiary holding paths retained.
| Company | Market | Ownership interest |
|---|---|---|
| Vicplas Holdings Pte. Ltd.Company; 2025 and 2024PDF p. 124 | Singapore; Manufacturing, trading and distributing of pipes and pipe fittings; FY2025 100%; FY2024 100% | |
| Rimplas Industries Sdn. Bhd.Company; 2025 and 2024PDF p. 124 | Malaysia; Manufacturing and distributing of pipes and pipe fittings; FY2025 100%; FY2024 100% | |
| Forefront Medical Technology (Pte) LtdCompany; 2025 and 2024PDF p. 124 | Singapore; Developing and manufacturing of medical devices; FY2025 100%; FY2024 100% | |
| Forefront Medical Investment Pte. Ltd.Subsidiary of Forefront Medical Technology (Pte) Ltd; 2025 and 2024PDF p. 124 | Singapore; Developing and manufacturing of medical devices; FY2025 100%; FY2024 100% | |
| Forefront Investment Pte. Ltd.Subsidiary of Forefront Medical Technology (Pte) Ltd; 2025 and 2024PDF p. 124 | Singapore; Investment holding; FY2025 100%; FY2024 100% | |
| XentiQ (Pte.) Ltd.Subsidiary of Forefront Medical Technology (Pte) Ltd; 2025 and 2024PDF p. 124 | Singapore; Project design and engineering services; FY2025 100%; FY2024 100% | |
| Forefront Medical Americas Pte. Ltd.Subsidiary of Forefront Medical Technology (Pte) Ltd; 2025 and 2024PDF p. 124 | Singapore; Manufacture of medical and dental tools, instruments and supplies; FY2025 100%; FY2024 100% | |
| Forefront (Xiamen) Medical Devices Co., LtdSubsidiary of Forefront Investment Pte. Ltd.; 2025 and 2024PDF p. 124 | People’s Republic of China; Manufacturing and assembly of medical devices; FY2025 100%; FY2024 100% | |
| Forefront Medical Technology (Jiangsu) Co., LtdSubsidiary of Forefront Medical Investment Pte. Ltd.; 2025 and 2024PDF p. 125 | People’s Republic of China; Manufacturing and assembly of medical devices; FY2025 100%; FY2024 100% | |
| Arrow Medical LimitedSubsidiary of Forefront Medical Investment Pte. Ltd.; 2025 and 2024PDF p. 125 | United Kingdom; Manufacturing and assembly of medical devices; FY2025 100%; FY2024 100% | |
| Arrow Medical Products LimitedSubsidiary of Arrow Medical Limited; 2025 and 2024PDF p. 125 | United Kingdom; Manufacturing and assembly of medical devices; FY2025 100%; FY2024 100% | |
| Vicplas Investment Pte. Ltd.Subsidiary of Vicplas Holdings Pte Ltd; 2025 and 2024PDF p. 125 | Singapore; Investment holding; FY2025 100%; FY2024 100% | |
| V&H Investment Co., LtdGroup joint venture; ownership interest and voting rights held by the Group; 2025 and 2024PDF p. 126 | Cambodia; Buying, selling and operating of self-owned or leased real estate; FY2025 49%; FY2024 49% | |
Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.
Senior executives
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Cheng Hsheng | Group Operations Director; Deputy Managing Director of the pipes and pipe fittings segment | Senior Management | PDF p. 11 |
| Gan Ying Hui | Chief Financial Officer | Senior Management | PDF p. 11 |
| Nor Hafiza Alwi | Company Secretary | Corporate information / Notice of AGM | PDF p. 151 |
Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.
Related parties, people & properties
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Venner Capital S.A. and subsidiaries and related parties | 1,086 S$'000 | Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 (excluding transactions less than S$100,000), FY2025 | PDF p. 55 |
| Legal fees expense | (73) $'000 | Group, 2025; entity in which a director is a partner (2024: (50)) | PDF p. 113 |
| Sale of goods | 1,086 $'000 | Group, 2025; group companies of the ultimate holding company (2024: 802) | PDF p. 113 |
| Compensation of directors and key management personnel | 2,550 $'000 | Group, 2025 (2024: 2,581) | PDF p. 113 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Guarantee given to banks and financial institutions for credit facilities granted to subsidiaries (unsecured) | 32,406 $'000 | Company, 2025 (2024: 29,727) | PDF p. 143 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Directors of the Company | 281 $'000 | Group, 2025 (2024: 285) | PDF p. 139 |
| FY2025 directors' fees | S$280,651 | FY2025 aggregate, subject to shareholder approval at AGM on November 28, 2025 | PDF p. 47 |
| Walter Tarca | 751,015 S$ | Group Chief Executive Officer (not a director), FY2025 | PDF p. 48 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| We currently employ 1,111 employees in Singapore, China, Malaysia and United Kingdom. | 1,111 employees | Group | PDF p. 19 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| OUTLOOK | the Group’s expectation is for revenue growth to be positive | FY2026, Chairman's statement | PDF p. 4 |
| OUTLOOK | While the Group remains cautiously optimistic | FY2026, Chairman's statement | PDF p. 4 |
Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.
Corporate information